Find your next M&A target

Target Asia + Worldwide M&A projects with our guidance on matching, planning, due diligence & implementation.

Project details

Korean biopharma company seeks investment.

Project region South Korea
Industry Biomedicine
Total value of the target N/A
Expected target net rate of return after deducting all taxes and fees N/A
Validity period of pending order 365

CONTACT ADVISOR

Project highlights patent for HA inducible factor - listed in KOSDAQ - 40 export countries
Project description

The Korean company began to expand its products since 2011, when it obtained the product licence of hyaluronic acid ("HA") injections. It has obtained the patent for manufacturing equipment and method of HA inducible factor. The company's anti-adhesion materials have obtained Good Manufacturing Practice ("GMP") certification and the collagen repair patch has obatined the medical device certification. The company has completed the botulinum toxin clinical phase I and II (phase III investigational new drug ("IND") application) trials, which were listed in the Korean Securities Dealers Automated Quotations ("KOSDAQ"). At present, the company's medical device factory in Daegu is a special factory for biomedical instruments, which can produce mesotherapy products such as HA/DNA injections, wound repair and tissue supplement materials, etc. in a modular manner. In the future, an Sejong GMP factory will be added for mass production of specialized medicines, bulk medicines, botulinum toxin, peptide for treating brain diseases, antiviral medicines for liver diseases, etc. In 2019, the company's export reached USD 6.24 million (KRW 7.8 billion) with 40 export countries. The company now seeks investment.

Enquire for more information about our services, and how we can help solve challenges for your organization

Contact Us
The code is case-sensitive